Table 4 Analysis of polymorphisms and lung cancer risk estimates
Repair | Gen | SNP | Genotype | Cases n (%) | Controls n (%) | Adjusteda OR [95% IC] | P | P trend |
|---|---|---|---|---|---|---|---|---|
NER | XPC | PAT | -/- | 172 (33.3) | 190 (35.6) | Reference | Â | Â |
|  |  |  | +/- | 243 (47.1) | 259 (48.6) | 1.08 [0.79–1.47] | 0.627 |  |
|  |  |  | +/+ | 101 (19.6) | 84 (15.8) | 1.28 [0.85–1.92] | 0.229 | 0.246 |
| Â | XPD | Asp312Asn | Asp/Asp | 240 (46.5) | 260 (48.8) | Reference | Â | Â |
|  |  |  | Asp/Asn | 221 (42.8) | 230 (43.1) | 1.01 [0.76–1.35] | 0.934 |  |
|  |  |  | Asn/Asn | 55 (10.7) | 43 (8.1) | 1.52 [0.91–2.51] | 0.106 | 0.232 |
| Â | Â | Lys751Gln | Lys/Lys | 222 (43.0) | 243 (45.6) | Reference | Â | Â |
|  |  |  | Lys/Gln | 237 (45.9) | 240 (45.0) | 1.12 [0.84–1.50] | 0.437 |  |
|  |  |  | Gln/Gln | 57 (11.1) | 50 (9.4) | 1.38 [0.85–2.25] | 0.193 | 0.181 |
BER | XRCC 1 | Arg399Gln | Arg/Arg | 222 (43.0) | 217 (40.7) | Reference | Â | Â |
|  |  |  | Arg/Gln | 219 (42.5) | 234 (43.9) | 0.86 [0.63–1.16] | 0.320 |  |
|  |  |  | Gln/Gln | 75 (14.5) | 82 (15.4) | 0.87 [0.57–1.31] | 0.500 | 0.672 |
DSBR | XRCC 3 | Thr241Met | Thr/Thr | 168 (41.7) | 178 (41.0) | Reference | Â | Â |
|  |  |  | Thr/Met | 185 (45.9) | 196 (45.2) | 1.06 [0.76–1.49] | 0.724 |  |
|  |  |  | Met/Met | 50 (12.4) | 60 (13.8) | 0.92 [0.56–1.50] | 0.898 | 0.898 |